Possible scenario
Pharma Partnership Expansion
25% Chance
OpenAI uses Orchestra Bio to sell agentic drug-development infrastructure to pharmaceutical and biotech partners. This outcome would fit the industry's growing willingness to outsource AI discovery workflows after Isomorphic's large 2026 financing validated the category.
Secondary impacts
- Technology +0.6%
- Healthcare +0.3%
- Business Services +0.1%
Tickers
- OBIO+9.1%
- MSFT+0.5%
- PFE+0.5%
- -0.3%
Portfolio impact
S&P 500+0.3%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.